Advertisement
Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at www.oncogenex.com. A replay of each webcast will be available for 30 days following the event.
Advertisement
About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.
- Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon at the New York Palace Hotel in New York City. - Thomas Weisel Partners Healthcare Conference on Friday, September 11, 2009 at 10:20 a.m. Eastern Time in the Stuart Room at the Four Seasons Hotel in Boston. - BioCentury NewsMakers in the Biotech Industry Conference on Wednesday, September 16, 2009 at 2:30 p.m. Eastern Time in room 304/305 at the Millennium Broadway Hotel & Conference Center in New York City.
SOURCE OncoGenex Pharmaceuticals, Inc.
